Pre-Exposure Prophylaxis
Conditions
Keywords
PreP
Brief summary
This is an interventional study investigating HPV carriage and liquid-based cytology at anal level. It will be offered to all patients undergoing PreP consultations at Besançon University Hospital. The anal swab will be taken by the doctor using a cyto-brush during the consultation.
Detailed description
The duration of participation in the study is 3 months for the submission of the results of the samples. A medical proctology consultation may also be offered, depending on the results of the screening. This will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections. A questionnaire will be completed by the doctor to record the data of interest. From additional data already entered in the e-NADIS software will be included for study.
Interventions
OTHERA prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections.
A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections. A questionnaire will be completed by the doctor to record the data of interest.
Sponsors
Centre Hospitalier Universitaire de Besancon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections. A questionnaire will be completed by the doctor to record the data of interest.
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Men sex Men Using Pre-exposure Prophylaxis for HIV Follow up au CHU de Besançon.
Exclusion criteria
* Women * No MSM * Under 18 * History of HPV related cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| prevalence HPV | day 1 | prevalence HPV |
| typing HPV | day 1 | typing HPV |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| High risk HPV risk factors | day 1 | High risk HPV risk factors |
| Cytologist abnormalies | day 1 | Cytologist abnormalies |
Countries
France
Contacts
Primary ContactCedric LEBRETON, Dr
Backup ContactIngrid TISSOT
Outcome results
None listed